$443 Pembrolizumab for BCG refractory non-muscle invasive bladder cancer yields poor recurrence-free survival and high toxicity in patients$

443 Pembrolizumab for BCG refractory non-muscle invasive bladder cancer yields poor recurrence-free survival and high toxicity in patients

Bibliographic Details
Main Authors:	Borivoj Golijanin, Vikas Bhatt, Ali Amin, Galina Lagos, Andre De Souza, Anthony E Mega, Dragan Golijanin
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer
by: Joshua J Meeks, et al.
Published: (2024-04-01)

Assessment of mechanical bowel preparation prior to nephrectomy in the minimally invasive surgery era: insights from a national database analysis in the United States
by: Stephen Schmit, et al.
Published: (2024-09-01)

CORRECTION: Assessment of mechanical bowel preparation prior to nephrectomy in the minimally invasive surgery era: insights from a national database analysis in the United States
by: Stephen Schmit, et al.
Published: (2024-12-01)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
by: Andres F. Correa, et al.
Published: (2015-01-01)

Geoecological evaluation of Ravna planina in the function of winter tourism
by: Golijanin Jelena
Published: (2011-01-01)

Мисиолошке импликације Чајкановићеве теорије о пореклу крсне славе
by: Vedran Golijanin
Published: (2023-04-01)

New Atheism and ‘Evil’ of Religions: The Call of Pastoral Theology for Building New Apologetics
by: Vedran Golijanin
Published: (2015-12-01)

Богословље на делу: Друштвена ангажованост Цркве у историјском, пастирском и мисиолошком контексту
by: Vedran Golijanin
Published: (2016-12-01)

Using Film in Orthodox Pastoral Practice
by: Vedran Golijanin
Published: (2022-11-01)

Ислам и Запад: Порекло и оправданост феномена исламофобије
by: Vedran Golijanin
Published: (2018-12-01)

Пасторално-мисиолошка анализа народне религиозности с посебним освртом на проблем култа предака
by: Vedran Golijanin
Published: (2018-12-01)

Пол Тилих и пастирско богословље
by: Vedran Golijanin
Published: (2019-12-01)

Путеви хришћанске инкултурације у Индији
by: Vedran Golijanin
Published: (2019-12-01)

P03.01 Efficacy and toxicity of BCG therapy in bladder cancer
by: S Acharya
Published: (2024-03-01)

The Concept of Learning in Classical Confucian Literature: The Four Books and Chinese Moral Education
by: Vedran Z. Golijanin
Published: (2024-07-01)

Landslides’ influence on the environment
by: Operta Mevlida, et al.
Published: (2013-01-01)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
by: Bedeir Ali-El-Dein, et al.
Published: (2013-01-01)

Bladder Cancer Immunotherapy: BCG and Beyond
by: Eric J. Askeland, et al.
Published: (2012-01-01)

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer
by: Sarah Lidagoster, et al.
Published: (2024-02-01)

Recognition and Treatment of BCG Failure in Bladder Cancer
by: Andrew J. Lightfoot, et al.
Published: (2011-01-01)

Transurethral Resection of the Prostate in Younger Men: Effectiveness and Long-Term Outcomes
by: Kamil Malshy, et al.
Published: (2024-04-01)

PemBla: a Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer
by: Woodcock, VK, et al.
Published: (2023)

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer
by: Victoria K. Woodcock, et al.
Published: (2023-05-01)

443 Team Science
by: Sayem Miah, et al.
Published: (2023-04-01)

Complication after the reconstruction of the old patellar tendon rupture
by: Ninković Srđan, et al.
Published: (2022-01-01)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
by: Uyen To, et al.
Published: (2014-01-01)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
by: S. Lukacs, et al.
Published: (2013-01-01)

Clinical activity of pembrolizumab in refractory -amplified advanced intimal sarcomas
by: Mauricio Fernando Ribeiro, et al.
Published: (2024-05-01)

Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge
by: Taro Ikeda, et al.
Published: (2021-01-01)

IMPACT OF POPULATION ON THE KARST OF EAST SARAJEVO (BOSNIA AND HERZEGOVINA)
by: Mariana Lukić Tanović, et al.
Published: (2019-08-01)

IMPACT OF POPULATION ON THE KARST OF EAST SARAJEVO (BOSNIA AND HERZEGOVINA)
by: Mariana Lukić Tanović, et al.
Published: (2019-08-01)

Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production
by: Enguang Yang, et al.
Published: (2024-09-01)

EBB443 - Technical Ceramics
by: PPKBSM, Pusat Pengajian Kejuruteraan Bahan dan Sumber Mineral

LEGAL BASIC OF BCG-THERAPY FOR BLADDER CANCER IN MUNICIPAL POLYCLINICS
by: M. M. Zorina, et al.
Published: (2016-10-01)

Pembrolizumab induced refractory ocular myasthenia gravis: A case report
by: Chaolan Zheng, et al.
Published: (2021-12-01)

Nail toxicity with nail bed ulceration associated with pembrolizumab
by: Shintaro Maeda, et al.
Published: (2023-12-01)

The safety and efficacy of low dose BCG intravesical instillation for the treatment of uremic or kidney transplant patients with recurrent urothelial carcinoma of the bladder
by: Wei-Ting Kuo, et al.
Published: (2016-06-01)

Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer
by: Andrew Leone, et al.
Published: (2015-01-01)

Locally Recurrent Leiomyoma of the Bladder Refractory to Visually Complete Transurethral Resection: An Indication for Cystoprostatectomy
by: Katharina Mitchell, et al.
Published: (2019-01-01)

Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
by: Guièze, R, et al.
Published: (2015)